TP53 and head and neck squamous cell carcinoma: Gendicine, a recombinant human p53 adenovirus developed by Shenzhen SiBiono GeneTech, was approved by the China Food and Drug Administration (CFDA) in 2003 for the treatment of head and neck squamous cell carcinoma (HNSCC).